Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
about
On and Under the Skin: Emerging Basidiomycetous Yeast Infections Caused by Trichosporon SpeciesCurrent knowledge of Trichosporon spp. and TrichosporonosisInvasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal PathogenPrimary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.Micafungin use in children.Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing.Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients.Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazoleEpidemiology of invasive fungal infections in the mediterranean areaMicafungin in the treatment of invasive candidiasis and invasive aspergillosisThree-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China.Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.Trichosporon faecale invasive infection in a patient with severe aplastic anemia: Efficacy of voriconazole and liposomal amphotericin B before neutrophil recovery.Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testEpidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014.Trichosporon fungemia in a pediatric patient with acute lymphoblastic leukemia.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testingRare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Managing fungal and viral infections in pediatric leukemia.Strategies to manage antifungal drug resistance.Uncommon yeast infections in hematological patients: from diagnosis to treatment.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Trichosporon asahii infection presenting as chronic meningo-ventriculitis and intra ventricular fungal ball: a case report and literature review.Trichosporonosis in Pediatric Patients With a Hematologic Disorder.Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen.Recurrent trichosporonosis with central nervous system involvement in an allogeneic hematopoietic stem cell transplant recipient.Switching of colony morphology and adhesion activity of Trichosporon asahii clinical isolates.Prompt diagnosis and effective treatment of Trichosporon asahii catheter-related infection in non-immunocompromised neurosurgical patient.Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae.KB425796-A, a novel antifungal antibiotic produced by Paenibacillus sp. 530603.Practical identification of eight medically important Trichosporon species by reverse line blot hybridization (RLB) assay and rolling circle amplification (RCA).Trichosporon inkin Esophagitis: An Uncommon Disease in a Patient with Pulmonary Cancer.Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.Successful treatment of breakthrough disseminated Trichosporon asahii fungemia in a patient with acute myeloid leukemia receiving itraconazole prophylaxis.Micafungin Breakthrough Fungemia in Patients with Hematological Disorders.Catheter-Related Trichosporon asahii Bloodstream Infection in a Neutropenic Patient with Myelodysplastic Syndrome.
P2860
Q26801428-0225105B-5841-4716-A3BF-995DC7D30720Q26998573-34E6F72D-66FA-468C-B807-DF874BAA3796Q28071847-52CA3DA2-4A3C-4356-A265-5C8892F9775BQ30840066-5F5558E9-18C6-4C46-876E-722D6DBF7EFDQ33397111-D7E17E25-592C-41D8-A90F-ED7DEFCA9650Q33410218-61660132-A428-4994-A28C-0A6426D2600CQ33450792-9FB79B2D-D493-47B4-8C0C-C9F601BB3951Q34470045-3DB9E95E-8EFA-4455-A788-0CCFE67A9B24Q35010686-79884C38-1FC9-4BC8-923D-929DB3DC20B7Q35026516-F58A4DBA-0EE6-441C-8FE0-62600A1A5BEEQ35530659-1A2106CC-37E3-4D2E-B46B-740E1A4AF81EQ35787372-B7CE9E98-8CF0-477C-B5E6-F0B4AD808272Q35864951-1A36A80C-12A2-4446-966A-F392928F8AC9Q35913918-A0758149-4C7A-4F2D-A49A-36831310BEA1Q36241645-0848B6B8-4E17-407C-9C56-50B189A8C167Q36460390-5EB141C1-FE9D-4D11-8702-59F5F2342C32Q36828156-5DEB337D-9712-4C2E-9E7C-40EEFB123EF0Q36895679-7F5B4F01-2300-4467-B1D4-21B01CC4C715Q37051529-22CB508E-18FD-451C-817A-C2E009F4995DQ37373824-FF9A7C5A-6DBF-4715-8A8B-28D82D346577Q37469829-3431578D-6B82-467B-8416-B39E0C95DC3FQ37810281-8074BA04-8ABC-41D6-8964-29025F0FD03AQ37827872-9B0F3884-4815-474D-AF0F-A0E9B5B36E2CQ37949642-ED1851BD-2A18-496D-8EA2-B9F9486EA8EAQ38284461-10E5F715-EC3C-47DC-8330-3EF10D71B7ACQ38318916-B2F69957-CDB8-4FD1-9A1E-45A353ED38C5Q38782786-CA3A330D-DD9C-4955-9667-3ECD3D3D4C33Q39093853-15DC4DA2-2782-46EB-AA05-191C1FC29CFFQ39212095-E0D1AB39-BB96-47A3-A092-287DE5E73B89Q40610770-09FA1B0C-1A9E-4A6A-996D-E07E1E3690DEQ40944870-6689413C-7422-49FA-94A4-A55EDC184311Q41728541-4AD62422-3EB0-49C7-BD4F-3A8CA2CA7894Q42035911-B6DB8518-9E10-4260-BAA8-0EF0ADC99297Q42258470-00549621-1902-4EB4-B274-490267F5DDA6Q44020544-5C0CABA8-B151-47D7-B67D-D7EBA9658468Q45200094-04A899C6-B67D-491C-96EA-FA5BA1735293Q46393306-88AC3799-3E2C-4F31-8412-50B35083C233Q47142755-201C7663-E819-43D0-BC49-5E1385B4AA5FQ54257520-02423E9D-953C-4F4E-A9E0-52E80D6101D8Q55519155-3F8C5030-78B0-43C2-AD55-8C19CF8650F3
P2860
Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@en
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@nl
type
label
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@en
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@nl
prefLabel
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@en
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@nl
P2093
P2860
P356
P1476
Breakthrough trichosporonosis ...... gnancies receiving micafungin.
@en
P2093
Hidetaka Uryu
Kosei Matsue
Masami Takeuchi
Mihoko Koseki
Noboru Asada
P2860
P304
P356
10.1086/500323
P407
P577
2006-02-08T00:00:00Z